Global Rare Kidney Diseases Market Report 2022 to 2035: by Target Indications, Type of Molecule, Route of Administration and Key Geographies

Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Rare Kidney Diseases Market by Target Indications, Type of Molecule, Route of Administration and Key Geographies: Industry Trends and Global Forecast, 2022-2035" report has been added to's offering.

This report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney diseases market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

The term rare kidney diseases (RKD) represents around 150 different indications. It is worth highlighting that the prevalence rate of rare kidney diseases is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disease.

The low incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis.

This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney diseases.

It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney diseases became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers.

Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney diseases.

Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in this domain have shifted their focus towards the development of drugs that can target a myriad of rare kidney diseases.

It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney diseases; these are (in reverse chronological order of approval) Galafold (Fabry disease, European Medicines Agency (EMA), 2021), LupkynisT (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), SibnayalT (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta (LN, USFDA, 2020), Cystadrops (Cystinosis, USFDA, 2020), and Ultomiris (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020).

Further, more than 90 candidates targeting rare kidney diseases are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in this domain since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.

One of the key objectives of this report was to evaluate the current market size and the future potential associated with rare kidney diseases market, over the coming years. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035.

Additionally, the report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous, and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of drugs targeting rare kidney diseases?
  • Which are the key drugs being developed across early and late stages of development?
  • Who are the key players providing services related to kidney care?
  • Which are the key indications targeted by drugs indicated for rare kidney diseases?
  • What type of partnership models are commonly adopted by stakeholders engaged in this domain?
  • Who are the key investors in the domain?
  • Which regions have emerged as the key hubs for conducting clinical studies focused on rare kidney diseases?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:



3.1. An Overview of rare kidney diseases
3.2. Key Historical Events
3.3. Factors Contributing to rare kidney diseases
3.4. rare kidney diseases: Target Indications
3.5. rare kidney diseases: Applications of Omics Technology
3.6. rare kidney diseases: Future Outlook

4.1. rare kidney diseases: List of Drugs
4.1.1. Analysis by Stage of Development
4.1.2. Analysis by Target Molecule
4.1.3. Analysis by Target Molecule and Route of Administration
4.1.4. Analysis by Target Indication
4.1.5. Analysis by Stage of Development and Target Indication
4.1.6. Analysis by Type of Target Molecule
4.1.7. Analysis by Stage of Development and Type of Target Molecule
4.2. rare kidney diseases: List of Drug Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Most Active Players: Analysis by Number of Drugs

5.1. Benlysta
5.1.1. Company Overview
5.1.2. Drug Overview
5.1.3. Clinical Trial Information
5.1.4. Clinical Trial Results
5.1.5. Estimated Sales Revenue
5.2. Cystadrops
5.2.1. Company Overview
5.2.2. Drug Overview
5.2.3. Clinical Trial Information
5.2.4. Clinical Trial Results
5.2.5. Estimated Sales Revenue
5.3. Galafold
5.3.1. Company Overview
5.3.2. Drug Overview
5.3.3. Clinical Trial Information
5.3.4. Clinical Trial Results
5.3.5. Estimated Sales Revenue
5.4. Tarpeyo
5.4.1. Company Overview
5.4.2. Drug Overview
5.4.3. Clinical Trial Information
5.4.4. Clinical Trial Results
5.4.5. Estimated Sales Revenue
5.5. Ultomiris
5.5.1. Company Overview
5.5.2. Drug Overview
5.5.3. Clinical Trial Information
5.5.4. Clinical Trial Results
5.5.5. Estimated Sales Revenue
5.6. Thiola
5.6.1. Company Overview
5.6.2. Drug Overview
5.6.3. Clinical Trial Information
5.6.4. Clinical Trial Results
5.6.5. Estimated Sales Revenue
5.7. LupkynisT
5.7.1. Company Overview
5.7.2. Drug Overview
5.7.3. Clinical Trial Information
5.7.4. Clinical Trial Results
5.7.5. Estimated Sales Revenue
5.8. SibnayalT
5.8.1. Company Overview
5.8.2. Drug Overview
5.8.3. Clinical Trial Information
5.8.4. Clinical Trial Results
5.8.5. Estimated Sales Revenue
5.9. Pegunigalsidase Alfa
5.9.1. Company Overview
5.9.2. Drug Overview
5.9.3. Clinical Trial Information
5.9.4. Clinical Trial Results
5.9.5. Estimated Sales Revenue
5.10. SaphneloT
5.10.1. Company Overview
5.10.2. Drug Overview
5.10.3. Clinical Trial Information
5.10.4. Clinical Trial Results
5.10.5. Estimated Sales Revenue
5.11. Atrasentan
5.11.1. Company Overview
5.11.2. Drug Overview
5.11.3. Clinical Trial Information
5.11.4. Clinical Trial Results
5.11.5. Estimated Sales Revenue
5.12. Bardoxolone Methyl
5.12.1. Company Overview
5.12.2. Drug Overview
5.12.3. Clinical Trial Information
5.12.4. Clinical Trial Results
5.12.5. Estimated Sales Revenue
5.13. Crovalimab
5.13.1. Company Overview
5.13.2. Drug Overview
5.13.3. Clinical Trial Information
5.13.4. Clinical Trial Results
5.13.5. Estimated Sales Revenue
5.14. Ianalumab
5.14.1. Company Overview
5.14.2. Drug Overview
5.14.3. Clinical Trial Information
5.14.4. Estimated Sales Revenue
5.15. Cozaar
5.15.1. Company Overview
5.15.2. Drug Overview
5.15.3. Clinical Trial Information
5.15.4. Clinical Trial Results
5.15.5. Estimated Sales Revenue
5.16. Cosentyx
5.16.1. Company Overview
5.16.2. Drug Overview
5.16.3. Clinical Trial Information
5.16.4. Estimated Sales Revenue
5.17. Empaveli
5.17.1. Company Overview
5.17.2. Drug Overview
5.17.3. Clinical Trial Information
5.17.4. Clinical Trial Results
5.17.5. Estimated Sales Revenue
5.18. Rituxan
5.18.1. Company Overview
5.18.2. Drug Overview
5.18.3. Clinical Trial Information
5.18.4. Clinical Trial Results
5.18.5. Estimated Sales Revenue
5.19. Sparsentan
5.19.1. Company Overview
5.19.2. Drug Overview
5.19.3. Clinical Trial Information
5.19.4. Clinical Trial Results
5.19.5. Estimated Sales Revenue
5.20. Iptacopan
5.20.1. Company Overview
5.20.2. Drug Overview
5.20.3. Clinical Trial Information
5.20.4. Clinical Trial Results
5.20.5. Estimated Sales Revenue
5.21. Narsoplimab
5.21.1. Company Overview
5.21.2. Drug Overview
5.21.3. Clinical Trial Information
5.21.4. Clinical Trial Results
5.21.5. Estimated Sales Revenue

6.1. Key Methodology and Parameters
6.2. Company Competitiveness Analysis: Biologic Developers (Peer Group 1)
6.3. Company Competitiveness Analysis: Small Molecule Developers (Peer Group 2)

7.1. rare kidney diseases: List of Partnerships
7.2. Analysis by Year of Partnership
7.3. Analysis by Type of Partnership
7.4. Analysis by Year and Type of Partnership
7.5. Analysis by Type of Partnership and Company Size
7.6. Analysis by Target Indication
7.7. Most Active Players: Analysis by Number of Partnerships
7.8. Analysis by Region
7.9. Analysis by Country
7.10. Intercontinental and Intracontinental Agreements

8.1. rare kidney diseases: List of Funding and Investments
8.2. Cumulative Year-wise Trend of Funding, 2016 - 2022
8.3. Analysis of Instances by Type of Funding
8.4. Analysis of Instances by Type of Venture Funding
8.5. Analysis of Instances by Year of Funding and Type of Funding
8.6. Analysis by Type of Funding and Amount Invested
8.7. Analysis of Instances by Type of Investor
8.8. Analysis by Focus Area
8.9. Analysis by Region
8.11. Most Active Investors: Analysis by Number of Instances
8.12. Most Active Players: Analysis by Number of Instances
8.13. Most Active Players: Analysis by Amount Raised (USD Million)

9.1. Methodology and Parameters
9.2. Cumulative Trend by Trial Registration Year, 2016 - 2022
9.3. Analysis by Target Indication
9.4. Analysis by Study Design
9.5. Analysis by Region
9.6. Analysis by Number of Trials, Phase of Development and Region
9.7. Analysis by Patient Age
9.8. Analysis by Trial Registration Year, Number of Trials and Region
9.9. Analysis by Trial Status and Phase of Development
9.10. Analysis of Patients Enrolled by Trial Registration Year
9.11. Analysis of Patients Enrolled by Phase of Development
9.12. Analysis by Number of Trials, Trial Status and Region
9.13. Analysis of Patients Enrolled by Region
9.14. Analysis of Patients Enrolled by Trial Status and Region






For more information about this report visit



Contact Data